Last reviewed · How we verify
TSI-GSD 200 RVF Vaccine
At a glance
| Generic name | TSI-GSD 200 RVF Vaccine |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated (PHASE2)
- Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine (PHASE2)
- Safety and Immunogenicity Study of Rift Valley Fever Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSI-GSD 200 RVF Vaccine CI brief — competitive landscape report
- TSI-GSD 200 RVF Vaccine updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI